Apremilast for RAS
A Pilot Study Evaluating the Efficacy of Apremilast in the Treatment of Subjects With Severe Recurrent Aphthous Stomatitis (RAS)
Sponsor: Celgene
A PHASE4 clinical study on Recurrent Aphthous Stomatitis, this trial is completed. The trial is conducted by Celgene and has accumulated 13 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Sep 2022 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 8 earlier versions
-
May 2022 — Sep 2022 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed · Phase: EARLY_PHASE1 → PHASE4
-
Oct 2021 — May 2022 [monthly]
Active Not Recruiting EARLY_PHASE1
-
May 2021 — Oct 2021 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting EARLY_PHASE1
-
May 2020 — Aug 2020 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — May 2020 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .